Home › Companies › Revolution Medicines, Inc. › 2025-2026
Compiled from SEC Form N-PX filings and Revolution Medicines, Inc.’s Form 8-K, filed June 22, 2026 (Item 5.07 on EDGAR). Page generated October 14, 2026.
Meeting of June 18, 2026: 4 items on Revolution Medicines, Inc.’s Form 8-K, filed June 22, 2026: 2 approved · 2 without a stated outcome.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Explore Revolution Medicines, Inc. in the interactive database Compare manager voting policies
These tallies are Revolution Medicines, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 22, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Alexis Borisy | 127,181,172 | -- | -- | 33,660,532 | 20,813,641 | 79% | Not verified | — |
| Elect Director: Mark A. Goldsmith, M.D., Ph.D. | 157,681,628 | -- | -- | 3,160,076 | 20,813,641 | 98% | Not verified | — |
| 2. The appointment, by the audit committee of the Company's board of directors, of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2026 | 181,309,783 | 206,306 | 139,256 | -- | -- | 99.8% | Approved | — |
| 3. On a non-binding, advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement, pursuant to the compensation disclosure rules of the SEC | 155,110,825 | 5,554,146 | 176,733 | -- | 20,813,641 | 97% | Approved | — |
Source: Revolution Medicines, Inc., Form 8-K, filed with the SEC on June 22, 2026 — read the filing on EDGAR.
Each item below shows how the 522 asset managers that disclosed a Revolution Medicines, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 8 wordings of this item as funds reported it.
79% Majority: yes · of votes cast
Description as filed by funds: To elect two Class III directors to hold office until the 2029 Annual Meeting of Stockholders or until his successor is elected: Alexis Borisy
Revolution Medicines, Inc.’s own tally for this item (“Elect Director: Alexis Borisy”): 127,181,172 for, 33,660,532 withheld, per its Form 8-K filed June 22, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 79% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 117 asset managers below reported 48,017,756 for, 3,764,147 withheld, 391,920 abstained, 235 not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 19,352,024 | 0 | 91 | 10,603 | For |
| Fidelity | 9,665,843 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 4,020,158 | 0 | 0 | 1,001,496 | Mixed |
| BlackRock | 4,194,817 | 0 | 0 | 0 | For |
| T. Rowe Price | 2,563,078 | 0 | 0 | 0 | For |
| Charles Schwab | 1,843,991 | 0 | 0 | 0 | For |
| State Street | 1,809 | 0 | 0 | 939,088 | Withhold |
| Columbia Threadneedle | 869,224 | 0 | 0 | 0 | For |
| Capital Group | 794,687 | 0 | 0 | 0 | For |
| Lord Abbett | 707,700 | 0 | 0 | 0 | For |
| Franklin Custodian Funds | 400,000 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 350,840 | Withhold |
| Victory Capital | 370 | 0 | 0 | 324,264 | Withhold |
| TIAA | 313,907 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 287,036 | 0 | 0 | 0 | For |
| JANUS ASPEN SERIES | 265,540 | 0 | 0 | 5,677 | For |
| Invesco | 260,273 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 257,218 | 0 | 0 | 0 | For |
| American Century | 0 | 0 | 0 | 239,067 | Withhold |
| MARSICO INVESTMENT FUND | 219,460 | 0 | 0 | 0 | For |
| Jackson National | 113,073 | 0 | 106,099 | 0 | Mixed |
| Goldman Sachs | 203,029 | 0 | 0 | 2,940 | For |
| MFS | 0 | 0 | 0 | 187,214 | Withhold |
| Bridge Builder Trust | 28,464 | 0 | 112,511 | 0 | Mixed |
| Equitable | 100,505 | 0 | 0 | 36,639 | Mixed |
Showing the 25 largest of 117 asset managers. See all 117 in the interactive database.
Combines 10 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Description as filed by funds: To elect two Class III directors to hold office until the 2029 Annual Meeting of Stockholders or until his successor is elected: Mark A. Goldsmith, M.D., Ph.D.
Revolution Medicines, Inc.’s own tally for this item (“Elect Director: Mark A. Goldsmith, M.D., Ph.D.”): 157,681,628 for, 3,160,076 withheld, per its Form 8-K filed June 22, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 117 asset managers below reported 51,605,888 for, 498,603 withheld, 69,332 abstained, 235 not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 19,362,706 | 0 | 11 | 0 | For |
| Fidelity | 9,665,843 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 5,021,654 | 0 | 0 | 0 | For |
| BlackRock | 4,194,817 | 0 | 0 | 0 | For |
| T. Rowe Price | 2,563,078 | 0 | 0 | 0 | For |
| Charles Schwab | 1,843,991 | 0 | 0 | 0 | For |
| State Street | 940,888 | 0 | 0 | 9 | For |
| Columbia Threadneedle | 869,224 | 0 | 0 | 0 | For |
| Capital Group | 794,687 | 0 | 0 | 0 | For |
| Lord Abbett | 707,700 | 0 | 0 | 0 | For |
| Franklin Custodian Funds | 400,000 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 350,840 | Withhold |
| Victory Capital | 324,634 | 0 | 0 | 0 | For |
| TIAA | 313,907 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 287,036 | 0 | 0 | 0 | For |
| JANUS ASPEN SERIES | 271,217 | 0 | 0 | 0 | For |
| Invesco | 260,273 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 257,218 | 0 | 0 | 0 | For |
| American Century | 239,067 | 0 | 0 | 0 | For |
| MARSICO INVESTMENT FUND | 219,460 | 0 | 0 | 0 | For |
| Jackson National | 216,063 | 0 | 3,109 | 0 | For |
| Goldman Sachs | 205,969 | 0 | 0 | 0 | For |
| MFS | 187,214 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 140,975 | 0 | 0 | 0 | For |
| Equitable | 100,505 | 0 | 0 | 36,639 | Mixed |
Showing the 25 largest of 117 asset managers. See all 117 in the interactive database.
Combines 19 wordings of this item as funds reported it.
97% Approved · of votes cast
Description as filed by funds: To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission ("Say-on-Pay").
Revolution Medicines, Inc.’s own tally for this item (“3. On a non-binding, advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement, pursuant to the compensation disclosure rules of the SEC”): 155,110,825 for, 5,554,146 against — passed, per its Form 8-K filed June 22, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement, pursuant to the compensation disclosure rules of the SEC.”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 19,346,996 | 13 | 0 | 0 | For |
| Fidelity | 9,665,843 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 5,021,654 | 0 | 0 | 0 | For |
| BlackRock | 4,194,817 | 0 | 0 | 0 | For |
| T. Rowe Price | 2,513,253 | 49,825 | 0 | 0 | For |
| Charles Schwab | 1,843,991 | 0 | 0 | 0 | For |
| State Street | 940,530 | 367 | 0 | 0 | For |
| Columbia Threadneedle | 869,224 | 0 | 0 | 0 | For |
| Capital Group | 0 | 794,687 | 0 | 0 | Against |
| Lord Abbett | 707,700 | 0 | 0 | 0 | For |
| Franklin Custodian Funds | 400,000 | 0 | 0 | 0 | For |
| Dimensional | 350,840 | 0 | 0 | 0 | For |
| Victory Capital | 324,634 | 0 | 0 | 0 | For |
| TIAA | 313,907 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 287,036 | 0 | 0 | 0 | For |
| JANUS ASPEN SERIES | 271,217 | 0 | 0 | 0 | For |
| Invesco | 0 | 260,273 | 0 | 0 | Against |
| MUTUAL FUND SERIES TRUST | 257,218 | 0 | 0 | 0 | For |
| American Century | 0 | 239,067 | 0 | 0 | Against |
| MARSICO INVESTMENT FUND | 219,460 | 0 | 0 | 0 | For |
| Jackson National | 219,172 | 0 | 0 | 0 | For |
| Goldman Sachs | 205,969 | 0 | 0 | 0 | For |
| MFS | 0 | 187,214 | 0 | 0 | Against |
| Bridge Builder Trust | 140,975 | 0 | 0 | 0 | For |
| Equitable | 137,144 | 0 | 0 | 0 | For |
Fund voting reports, all 117 managers: 50,405,632 for, 1,761,274 against, 850 abstained, 235 not voted. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Janus Henderson | 21,654,005 | 9,898 | 0 | 0 | For |
| FARALLON CAPITAL MANAGEMENT, L.L.C. | 14,135,270 | 0 | 0 | 0 | For |
| Fidelity | 10,395,054 | 1,279 | 0 | 0 | For |
| BlackRock | 6,737,075 | 28,659 | 0 | 0 | For |
| Darwin Global Management, Ltd. | 5,779,848 | 0 | 0 | 0 | For |
| Paradigm Biocapital Advisors LP | 5,094,491 | 0 | 0 | 0 | For |
| Wellington | 4,408,510 | 0 | 0 | 0 | For |
| Nextech Invest Ltd. | 4,010,774 | 0 | 0 | 0 | For |
| T. Rowe Price | 3,781,570 | 76,880 | 0 | 0 | For |
| BVF INC/IL | 3,581,782 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 3,539,327 | 0 | 0 | 0 | For |
| State Street | 3,021,493 | 40,955 | 0 | 0 | For |
| GV Management Company, L.L.C. | 2,946,619 | 0 | 0 | 0 | For |
| Casdin Capital, LLC | 2,577,333 | 0 | 0 | 0 | For |
| Woodline Partners LP | 2,276,903 | 0 | 0 | 0 | For |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 2,256,108 | 0 | 0 | 0 | For |
| Polar Capital Holdings Plc | 2,144,954 | 0 | 0 | 0 | For |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 2,088,274 | 0 | 0 | 0 | For |
| Charles Schwab | 1,880,976 | 0 | 0 | 0 | For |
| Caligan Partners LP | 1,583,652 | 0 | 0 | 0 | For |
| Vanguard | 1,481,944 | 0 | 0 | 0 | For |
| Holocene Advisors, LP | 1,407,344 | 0 | 0 | 0 | For |
| Rock Springs Capital Management LP | 1,246,216 | 0 | 0 | 0 | For |
| Vestal Point Capital, LP | 1,231,298 | 0 | 0 | 0 | For |
| Logos Global Management LP | 1,086,713 | 0 | 0 | 0 | For |
Institutional-manager reports, all 433 managers: 131,833,067 for, 4,485,968 against, 380,102 abstained, 3,687 not voted. Showing the 25 largest; see all in the interactive database.
Combines 5 wordings of this item as funds reported it.
99.8% Approved · of votes cast
Description as filed by funds: To ratify the appointment, by the Audit Committee of the Company's Board of Directors, of PricewaterhouseCoopers LLP, as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026; and
Revolution Medicines, Inc.’s own tally for this item (“2. The appointment, by the audit committee of the Company's board of directors, of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 20”): 181,309,783 for, 206,306 against — passed, per its Form 8-K filed June 22, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders ratified the appointment, by the audit committee of the Company's board of directors, of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2026.”
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 118 asset managers below reported 52,167,128 for, 26 against, 850 abstained, 235 not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 19,347,008 | 0 | 0 | 0 | For |
| Fidelity | 9,665,843 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 5,021,654 | 0 | 0 | 0 | For |
| BlackRock | 4,194,817 | 0 | 0 | 0 | For |
| T. Rowe Price | 2,563,078 | 0 | 0 | 0 | For |
| Charles Schwab | 1,843,991 | 0 | 0 | 0 | For |
| State Street | 940,871 | 26 | 0 | 0 | For |
| Columbia Threadneedle | 869,224 | 0 | 0 | 0 | For |
| Capital Group | 794,687 | 0 | 0 | 0 | For |
| Lord Abbett | 707,700 | 0 | 0 | 0 | For |
| Franklin Custodian Funds | 400,000 | 0 | 0 | 0 | For |
| Dimensional | 350,840 | 0 | 0 | 0 | For |
| Victory Capital | 324,634 | 0 | 0 | 0 | For |
| TIAA | 313,907 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 287,036 | 0 | 0 | 0 | For |
| JANUS ASPEN SERIES | 271,217 | 0 | 0 | 0 | For |
| Invesco | 260,273 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 257,218 | 0 | 0 | 0 | For |
| American Century | 239,067 | 0 | 0 | 0 | For |
| MARSICO INVESTMENT FUND | 219,460 | 0 | 0 | 0 | For |
| Jackson National | 219,172 | 0 | 0 | 0 | For |
| Goldman Sachs | 205,969 | 0 | 0 | 0 | For |
| MFS | 187,214 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 140,975 | 0 | 0 | 0 | For |
| Equitable | 137,144 | 0 | 0 | 0 | For |
Showing the 25 largest of 118 asset managers. See all 118 in the interactive database.
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 200,178,626 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 9.66% |
| 2 | Fidelity | 4.83% |
| 3 | JANUS INVESTMENT FUND | 2.51% |
| 4 | BlackRock | 2.10% |
| 5 | T. Rowe Price | 1.28% |
| 6 | Charles Schwab | 0.92% |
| 7 | State Street | 0.47% |
| 8 | Columbia Threadneedle | 0.43% |
| 9 | Capital Group | 0.40% |
| 10 | Lord Abbett | 0.35% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Janus Henderson | 10.82% |
| 2 | FARALLON CAPITAL MANAGEMENT, L.L.C. | 7.06% |
| 3 | Fidelity | 5.19% |
| 4 | BlackRock | 3.38% |
| 5 | Darwin Global Management, Ltd. | 2.89% |
| 6 | Paradigm Biocapital Advisors LP | 2.54% |
| 7 | Wellington | 2.20% |
| 8 | Nextech Invest Ltd. | 2.00% |
| 9 | T. Rowe Price | 1.93% |
| 10 | BVF INC/IL | 1.79% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| Vanguard Group | 8.35% | 13F |
| Entities affiliated with Farallon Capital Partners, L.P. | 7.23% | DEF14A |
| Baker Bros. Advisors LP | 5.72% | 13G |
| Entities affiliated with Janus Henderson Group PLC | 5.67% | DEF14A |
| BlackRock | 5.60% | 13F |
| JANUS HENDERSON GROUP PLC | 4.88% | 13G |
| FMR (Fidelity) | 4.23% | 13F |
| Thilo Schroeder, Ph.D. | 3.80% | DEF14A |
| Wellington Management | 3.01% | 13F |
| State Street | 2.20% | 13F |
Percentages above are of 200,178,626 shares outstanding, as reported by Revolution Medicines, Inc. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Revolution Medicines, Inc.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on October 14, 2026; a live search always shows the current data.
At Revolution Medicines, Inc.'s shareholder meeting held June 18, 2026, in the 2025-2026 proxy season, 522 asset managers reported how they voted on 4 ballot items in their SEC Form N-PX filings, covering 2,559 separate fund positions. On the most widely held item on that ballot — To approve, on a non-binding, advisory basis, the compensation of the Company's named executive… — Revolution Medicines, Inc.'s filing reports the proposal as approved, with 97% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Revolution Medicines, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 22, 2026.
Revolution Medicines, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).
Download data (CSV): ballot items · votes by manager · column guide.